<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987740</url>
  </required_header>
  <id_info>
    <org_study_id>HL-CA-2000</org_study_id>
    <nct_id>NCT00987740</nct_id>
  </id_info>
  <brief_title>Feasibility Study of the Hemolung Respiratory Assist System</brief_title>
  <official_title>A Prospective, Non-Randomized Feasibility Study of the Hemolung Respiratory Assist System in COPD Patients With Acute Respiratory Failure That Are at a 50% Risk of Failing Non Invasive Ventilation (NIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alung Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alung Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the Hemolung Respiratory&#xD;
      Assist System in patients with hypercapnic respiratory failure associated with acute&#xD;
      exacerbation of chronic obstructive pulmonary disease (COPD) and a 50% likelihood of failure&#xD;
      of noninvasive positive pressure ventilation leading to intubation and mechanical&#xD;
      ventilation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of serious adverse events while on Hemolung therapy and up to 30 days after cessation of therapy and decannulation.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients requiring Mechanical Ventilation</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in patient self assessment of dyspnea using visual analog scale pre- to post-Hemolung therapy.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Minute Volume (VE) pre- to end-Hemolung therapy</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in the ICU</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in the hospital</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive and off mechanical ventilation for &gt; 48 hours through the end of Day 30 following completion of Hemolung therapy</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients requiring sedation, and hours of sedation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on Non-Invasive Positive Pressure Ventilation (NIPPV)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For patients requiring Mechanical Ventilation, number of days on Mechanical Ventilation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of weaning time from NIPPV</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of weaning time from Hemolung therapy</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hypercapnic Respiratory Failure, COPD</condition>
  <arm_group>
    <arm_group_label>Hemolung Respiratory Assist System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemolung Respiratory Assist System</intervention_name>
    <description>Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.</description>
    <arm_group_label>Hemolung Respiratory Assist System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate or severe COPD, as defined by the GOLD criteria&#xD;
&#xD;
          -  Acute exacerbation of COPD (sustained worsening of patient's condition necessitating a&#xD;
             change in regular medication)&#xD;
&#xD;
          -  On non-invasive positive pressure mechanical ventilation &gt; 1hour with either:&#xD;
&#xD;
          -  PaCO2 &gt; 55 mmHg with pH &lt; 7.25 OR&#xD;
&#xD;
          -  PaCO2 &gt; 55 mmHg with &lt; 5mmHg decrease from baseline and pH &lt; 7.30&#xD;
&#xD;
          -  Not severely hypoxemic (PaO2/FiO2 ≥ 200 mmHg on PEEP/CPAP ≤ 5 cmH2O)&#xD;
&#xD;
          -  Hemodynamically stable (mean arterial pressure &gt; 65 mmHg without vasopressor support)&#xD;
&#xD;
          -  Chronic arrhythmias (e.g., atrial fibrillation) well controlled&#xD;
&#xD;
          -  Minimum platelet count of 100,000/mm3&#xD;
&#xD;
          -  Minimum red blood cell count of 2.5 mill/μl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of acute, uncontrolled arrhythmia&#xD;
&#xD;
          -  Acute ischemic heart disease&#xD;
&#xD;
          -  Presence of bleeding diathesis&#xD;
&#xD;
          -  Significant abnormality or weakness/paralysis of respiratory muscles due to a know&#xD;
             muscular dystrophy or neurologic disorder&#xD;
&#xD;
          -  Recent (&lt; 7 days) prolonged (&gt;24 hrs) use of muscle paralyzing agents&#xD;
&#xD;
          -  Cerebrovascular accident, intracranial bleed, head injury or other neurologic disorder&#xD;
             likely to affect ventilation&#xD;
&#xD;
          -  Coma from any cause, or decreased consciousness&#xD;
&#xD;
          -  Hypersensitivity to heparin or previous heparin induced thrombocytopenia&#xD;
&#xD;
          -  Recent (&lt; 6 months) major chest abdominal trauma or surgery&#xD;
&#xD;
          -  Presence of septic shock&#xD;
&#xD;
          -  Presence of a significant pneumothorax or bronchopleural fistula&#xD;
&#xD;
          -  History of uncontrolled major psychiatric disorder&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Known to have AIDS or to have symptomatic HIV&#xD;
&#xD;
          -  Received chemotherapy or radiation within the previous 90 days&#xD;
&#xD;
          -  Received an organ transplant other than corneal transplants&#xD;
&#xD;
          -  Received or currently receiving immunosuppressive therapy, excluding corticosteroids&#xD;
             within the last 3 months&#xD;
&#xD;
          -  Presence of severe renal or liver failures&#xD;
&#xD;
          -  Known vascular abnormality with could complicate or prevent successful insertion of&#xD;
             the vascular access catheter in the right femoral vein&#xD;
&#xD;
          -  Presence of another catheter in the right femoral vein that cannot be moved&#xD;
&#xD;
          -  Presence of an inferior vena cava filter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RK Mani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Artemis Health Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Artemis Health Institute</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercapnic respiratory failure, COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypercapnia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

